Massive Bio and CureMatch Announce Groundbreaking Partnership to Revolutionize Cancer Treatment through AI and Clinical Trial Accessibility

(Massive Bio and CureMatch have joined forces in a transformative partnership aimed at revolutionizing cancer treatment. The partnership accelerates the drug development process, offers faster access to advanced therapies, and aims to reduce disparities in clinical trial participation.)

NEW YORK--(BUSINESS WIRE)--Massive Bio, an AI-powered platform connecting patients with clinical trials and CureMatch, a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision medicine support for oncology, and have announced a transformative partnership aimed at revolutionizing cancer treatment through advanced genomics, artificial intelligence, and expansive clinical trial accessibility.

Massive Bio and CureMatch will leverage their cutting-edge technologies to provide oncologists and their patients unprecedented access to potentially lifesaving clinical trials, personalized cancer treatments, and comprehensive reports on the most effective therapies based on individual patients' profiles.

Selin Kurnaz, CEO and Co-Founder of Massive Bio, highlights the potential of this alliance: "This partnership with CureMatch combines the power of precision medicine with the most advanced AI-driven clinical trial matching. It disruptively accelerates the drug development process, offering faster access to advanced therapies for patients."

Navid Alipour, CEO of CureMatch, also emphasized the transformative potential of the partnership. "CureMatch is thrilled to join forces with Massive Bio. By integrating our personalized oncology platform with their AI-driven clinical trial matching system, we can reach more patients and provide the best possible treatment options. Our mission is to improve the quality of life for countless patients and contribute to the global fight against cancer."

In this game-changing alliance, CureMatch will harness its distinctive platform to identify patients who stand to benefit most from groundbreaking clinical trials, thereby magnifying the reach and impact of Massive Bio's trials. Simultaneously, Massive Bio will employ its cutting-edge AI capabilities to process a wealth of patient clinical health data, including variables such as cancer type, demographics, geographic location, and historical data. By weaving this intricate data mosaic with CureMatch's customized reports, Massive Bio will expertly determine potential matches for appropriate clinical trials. This pioneering approach not only streamlines patient identification but also propels drug development and fortifies personalized treatment strategies. As a result, this transformative partnership presents a highly compelling opportunity for similar future partners looking to fuel the future of precision oncology.

Dr. Arturo Loaiza-Bonilla, Co-Founder of Massive Bio, believes the collaboration will not only contribute to cancer treatment innovation but will also play a vital role in reducing disparities in clinical trial participation. "This partnership addresses a critical gap in oncology research, providing an opportunity for all patients, regardless of their geographical location, to access cutting-edge treatments."

By leveraging the expertise and technological capabilities of both organizations, the partnership aims to facilitate the referral of patients to clinical trials, thus increasing access to potential therapies for cancer patients. As a result, patients worldwide stand to benefit from advanced precision medicine delivered locally, improving health outcomes and reducing healthcare costs.

About Massive Bio

Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries. For further details, please visit www.massivebio.com, https://askfiona.ai, https://drarturo.ai or interact with us on our social media channels.

About CureMatch

CureMatch, Inc. is a digital health company focused on personalized medicine and combination therapy in oncology. CureMatch's Decision Support System guides oncologists in the selection of cancer drugs that are personalized for individual patients based on their molecular tumor profile.